# Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

> **NCT03262454** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 35 (estimated)

## Conditions studied

- Small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03262454
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-22
- **Primary completion:** 2023-02-23
- **Final completion:** 2024-07-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03262454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03262454, "Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03262454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*